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The Gorlin-Goltz syndrome, also known as ne-
void basal cell carcinoma (BCC), has a variable preva-
lence, estimated from 1/57,000 to 1:256,000 inhabit-
ants (1). It is a rare autosomal dominant disorder due 
to a genetic mutation in the PTCH tumor suppressor 
gene localized to 9q22.3 chromosome (2).
In order to make a diagnosis of Gorlin-Goltz syn-
drome, some diagnostic criteria have to be taken into 
account. The most important criteria are the presence 
of pigmented BCCs, odontogenic keratocysts, palmar 
and/or plantar pits, and ectopic calcifications of the 
falx cerebri. Together with these major criteria, more 
than 100 minor clinical signs have been described. 
Diagnosis can be established when two major or one 
major and two minor criteria are present (3) (Table 
1). 
Basal cell carcinomas are seen in 50%-97% of all 
cases. Some differences have been described be-
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tween the BCCs of patients not affected by the syn-
drome and those with the syndrome. In the latter, they 
are more likely to be multiple lesions, polymorphic in 
nature, in either sex, and even areas not exposed to 
sunlight can be affected (4). They are not histologi-
cally different, but show a higher rate of recurrence 
after treatment than in non-syndrome patients. The 
cosmetic consequences are more important because 
of their multiplicity (5).
There are many therapeutic alternatives for BCCs. 
Surgical excision is the first usual approach, but some-
times for multifocal or large size lesions, this is not the 
best choice.
Electrochemotherapy (ECT) is a tumor ablation 
modality for cutaneous and subcutaneous lesions 
from different malignancies, including BCC. This com-
bines conventional chemotherapeutic drugs (bleo-









• Multiple basal cell carcinomas or 
one occurring under the age of 20 
years.
• Histologically proven OKCs of the 
jaws.
• Palmar or plantar pits (three or 
more).
• Bilamellar calcifications of the falx 
cerebri.
• Bifid, fused, or markedly splayed 
ribs.
• First degree relative with nevoid 









• Macrocephaly (adjusted for height).
• Congenital malformation: Cleft lip or 
cleft palate, frontal bossing, coarse face 
moderate or severe hypertelorism.
• Other skeletal abnormalities: Sprengel 
deformity, marked pectus deformity, 
marked syndactyly of the digits.
• Radiological abnormalities: Bulging of sella 
turcica, vertebral anomalies such as hemi 
vertebrae, fusion or elongation of vertebral 
bodies, modeling defects of the hands and 
feet, or flame-shaped hands or feet.
• Ovarian fibroma.
• Medulloblastoma.
Table 1.  Diagnostic criteria for Gorlin-Goltz syndrome
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Since 1995, literature reports very good rates of 
response, up to 90%, of cutaneous and subcutaneous 
metastases treated with ECT and bleomycin adminis-
tered intravenously or intralesionally (6).
A 43-year-old man was referred to our Depart-
ment. He had a large painless, erythematosus and ul-
cerated plaque on the scalp, which had first appeared 
two years earlier and was growing slowly. The size of 
the lesion ranged from 5 cm to 10 cm in diameter (Fig. 
1). An incisional biopsy was performed and the diag-
nosis of BCC was made.
Clinical examination revealed the presence of 
other BBCs localized on the trunk and preauricular re-
gion. Other BBCs had been previously removed from 
his scalp, face, leg and abdomen; most of these pro-
cedures entailed complex surgical closures, which 
were undertaken by plastic surgeons. 
There was also pitting on palmar and plantar sur-
faces and typical skeletal malformations such as fron-
tal bossing, depressed nasal bridge, prominent su-
praorbital ridges and mandibular prognathism. 
The diagnosis of Gorlin-Goltz syndrome was 
made. Surgery was excluded due to the tumor exten-
sion. So, after careful consideration, we decided to 
refer the patient to a sitting of electrochemotherapy. 
It was performed with deep sedation; bleomycin was 
administered intravenously at a dose of 15 mg/m2. 
We used an electric pulse generator, the Clinipora-
tor®, and a hexagonal needle electrode of 20 mm in 
length (IGEA S.r.l.). After eight minutes, the electrode 
was inserted directly into the lesion, covering the 
whole area. Sequences of eight pulses of 680 V for 
nodule were delivered at a frequency of 5 KHz and 
duration of 100 μs. The treatment was finished at 20 
minutes after the end of the infusion, to ensure an 
adequate concentration of bleomycin in tumoral tis-
sues. After ECT, the patient was kept under observa-
tion for 24 hours.
Initially, the treated surface appeared erythema-
tous and edematous. Later, a superficial necrotic es-
char had formed on the nodule for about four weeks, 
when complete re-epithelialization was observed. 
The patient had residual pain on treatment areas for 
less than two weeks, then it decreased after anti-in-
flammatory therapy.
After one-month follow up, we decided for a sec-
ond treatment to achieve complete remission. This 
ECT session was performed with the same criteria as 
the first one. After two weeks, the lesion had almost 
vanished and the surface had become flattened; after 
four weeks, we observed complete response of the 
treated area, understood as no palpable tumor de-
tected (7). Other BBCs, superficial at the time of diag-
nosis, were treated with cryotherapy and imiquimod 
5%.
In the following months, we followed up the 
patient and we treated new suspected hotbeds 
with several sessions of cryotherapy. After four-year 
follow up, there was clinical evidence of complete 
recovery and no sign of local relapses (Fig. 2).
Therapy for clinical manifestations of Gorlin-Goltz 
syndrome is not a simple treatment.
Basal cell carcinomas in this syndrome have a 
multiple-modality treatment: surgical excision, Mohs 
micrographic surgery, electrodesiccation, topical flu-
orouracil, cryotherapy, topical imiquimod and photo-
dynamic therapy, and carbon dioxide laser vaporiza-
tion (8). Multiple BBCs, present in this disease, require 
numerous surgical procedures that over time leave 
them with multiple disfiguring scars. 
Surgical intervention, although efficient, may be 
too painful and discomforting and may increase mor-
bidity, especially if it has to be frequently performed. 
For this reason, we decided to use ECT.
Electrochemotherapy combines the electropul-
sation of tumor cells (by local application of electric 
pulses) and the administration of antineoplastic drugs 
such as cisplatin or bleomycin (either intravenous or 
intratumoral). The permeability of the cancer cells to 
these poorly permeating anti-tumor drugs is tran-
siently increased up to hundred-fold. This approach 
Figure 1. Erythematous and ulcerated plaque 5 cm x 
10 cm on the scalp
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has been shown to be highly effective in providing 
local control of cutaneous or subcutaneous tumors, 
regardless of their histologic origin, while maintain-
ing a very low toxicity profile and high patient com-
pliance (9).
Recent discoveries suggest that in addition to the 
direct cytotoxic effect of  ECT on tumor cells, there 
may also be an indirect effect on the tumor, de-
creasing the blood flow with consequent extensive 
tumor necrosis (10). It has also been proposed that 
ECT might allow tumor antigen shedding and local 
inflammation, thus attracting immune antigen-pre-
senting cells (11).
In our case, we have obtained complete response, 
showing that ECT is feasible and effective on unre-
sectable BCCs. The advantages of this therapy are its 
simplicity, the short duration of treatment sessions, 
insignificant side effects, and repeatability. In addi-
tion, ECT has the advantage of achieving good local 
tissue preservation, less scarring and a good cosmetic 
outcome, thus improving the quality of life.
We think that ECT may represent a treatment of 
choice in cases of multiple and unresectable BCCs in 
this pathology. 
References
1. Jawa DS, Sircar K, Somani R, Grover N, Jaidka 
S, Singh S. Gorlin-Goltz syndrome. J Oral Maxillo-
fac Pathol 2009;13:89-92.
2. Ljubenovic M, Ljubenovic D, Binic I, Jovanovic D, 
Stanojevic M. Gorlin-Goltz syndrome. Acta Der-
matovenerol Alp Panonica Adriat 2007;16:166-9. 
3. Joshi PS, Deshmukh V, Golgire S. Gorlin-Goltz syn-
drome. Dent Res J (Isfahan) 2012;9:100-6.
4. Sirous M, Tayari N. A case report of Gorlin-
Goltz syndrome as a rare hereditary disorder. J 
Res Med Sci 2011;16:836-40.
5. Reyes Macias JF, Bagán Sebastián JV. Síndrome de 
Gorlin-Goltz Revisión de la literatura y reporte de 
un caso. Rev Eur Odontoestomatol 2002;14:105-12.
6. Escoffre JM, Rols MP. Electrochemotherapy: pro-
gress and prospects. Curr Pharm Des 2012 Mar 8. 
7. WHO. Handbook for reporting results of cancer 
treatment. Geneva: World Health Organization, 
1997;22-7.
8. Ferreres JR, Macaya A, Jucglà A, Muniesa C, Prats 
C, Peyrí J. Hundreds of basal cell carcinomas in 
a Gorlin-Goltz syndrome patient cured with imi-
quimod 5% cream. J Eur Acad Dermatol Venere-
ol 2006;20:877-8.
9. Reinhold U. Electrochemotherapy  for  primary 
skin  cancer  and  skin  metastasis related to other 
malignancies. Anticancer Drugs 2011;22:711-8. 
10. Kimonis VE, Mehta SG, DiGiovanna JJ, Bale SJ, Pas-
takia B. Radiological features in 82 patients with 
nevoid basal cell carcinoma (NBCC or Gorlin) syn-
drome.  Genet Med 2004;6:495-502. 
11. Glass LF, Fenske NA, Jaroszeski M, Perrott R, Har-
vey DT, Reintgen DS, et al. Bleomycin-media-
ted electrochemotherapy of basal cell carcinoma. 
J Am Acad Dermatol 1996;34:82-6. 
Pietro Curatolo, Emanuele Miraglia, 
Roberta Rotunno, Stefano Calvieri, Sandra Giustini





Policlinico Umberto I, Sapienza




Received: April 24, 2012 
Accepted: March 15, 2013
Figure 2. Complete remission and no sign of local re-
lapses after four years of follow up
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